Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Ensartinib group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial -
Epo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Premature Infant
1 trial -
Erlotinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small-cell Lung Cancer
1 trial -
Erythropoietin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Premature Infants
1 trial -
Etoposide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
FOLFOX/FOLFIRI
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Unresectable or Metastatic Colorectal Cancer
1 trial -
FOLFOXIRI
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Cancer
1 trial -
FOLFOXIRI-based HAIC+Fuquinitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Neoplasms
1 trial -
Famitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Favipiravir
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Influenza, Human
1 trial -
Fecal microbiota transplantation (FMT)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Slow Transit Constipation
1 trial -
Fludarabine (FLU)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aplastic Anemia Idiopathic
1 trial -
Freeze-dried, Capsulized FMT
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Slow Transit Constipation
1 trial -
Fruquintinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rectal Cancer
1 trial -
Fruquintinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Fruquintinib
1 trial -
Furmonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Adenocarcinoma Stage III
1 trial -
Furmonertinib in combination with Anrotinib and chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer (NSCLC)
1 trial -
GSPE
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Atherosclerosis of Arteries of the Extremities, Unspecified
1 trial -
GT719 Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hematological Malignancy (Leukemia- Lymphoma)
1 trial -
GVMΒ±R regimen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T Cell Lymphoma
1 trial -
Gastrograο¬n
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Fecal Impaction
1 trial -
Gecacitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
cGVHD
1 trial -
Gemcitabine , Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sarcoma
1 trial -
Gemcitabine 1000 mg
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase II, Open-label, Parallel 2-arm, Multi-center
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources